ABT vs VG · P/E 25, rev $44.33B vs P/E 11, rev $13.77B
Abbott Laboratories (ABT) versus Venture Global, Inc. (VG) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Venture Global, Inc. (VG) is a oil & gas midstream company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported VG revenue for 2025-12-31 was $13.77B. Net income was $2.73B. Revenue was up 176.9% from 2024-12-31 to 2025-12-31. VG currently screens at market cap $26.69B and trailing P/E 11.2.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. VG currently screens at market cap $26.69B and trailing P/E 11.2.
Not investment advice. Open the ABT and VG stock pages for the full models.
Not investment advice.